Vey N, Blaise D, Tiberghien P, Attal M, Pico J L, Reiffers J, Harrousseau J L, Fiere D, Tabilio A, Gabus R, Brandely M, Maraninchi D
Institut Paoli-Calmettes Marseille, France.
Leuk Lymphoma. 1996 Mar;21(1-2):107-14. doi: 10.3109/10428199609067587.
In this study, we investigated the impact of recombinant interleukin-2 (rIL-2) after high dose chemotherapy and autologous bone marrow transplantation (ABMT) in 25 patients with refractory or relapsed Hodgkin's disease (HD) (11 patients) and non Hodgkin's lymphoma (NHL) (14 patients). 48% of patients had resistant disease, 84% achieved complete remission after ABMT. rIL-2 was started at a median of 54 days post-transplant and consisted of a first cycle of 5 days followed by 4 cycles of 2 days every other week. Patients received a mean of 160 x 10(6) IU/m2 rIL-2 and hematological toxicity was moderate and transient. None of the 5 evaluable patients with measurable disease responded to rIL-2. After a 5 year median follow-up, the probability of survival and DFS is 72% (HD: 73% and NHL: 70%, p = NS) and 45% (HD: 36% and NHL: 48%, p = NS) respectively. These somewhat encouraging results warrant further evaluation of rIL-2 after ABMT in controlled studies, especially in NHL patients stratified for previous chemosensitivity.
在本研究中，我们调查了重组白细胞介素-2（rIL-2）在25例难治性或复发性霍奇金淋巴瘤（HD）（11例）和非霍奇金淋巴瘤（NHL）（14例）患者接受大剂量化疗和自体骨髓移植（ABMT）后的作用。48%的患者患有耐药性疾病，84%的患者在ABMT后实现完全缓解。rIL-2在移植后中位数54天开始使用，第一个周期为5天，随后每隔一周进行4个周期，每个周期2天。患者平均接受160×10⁶IU/m²的rIL-2，血液学毒性为中度且短暂。5例可评估的有可测量疾病的患者中，无一例对rIL-2有反应。经过中位数5年的随访，生存率和无病生存率分别为72%（HD：73%，NHL：70%，p=无显著性差异）和45%（HD：36%，NHL：48%，p=无显著性差异）。这些结果有些令人鼓舞，有必要在对照研究中进一步评估ABMT后rIL-2的作用，特别是在根据先前化疗敏感性分层的NHL患者中。
